-+ 0.00%
-+ 0.00%
-+ 0.00%
Hengrui Pharmaceutical announced that the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, involving 5 types of drugs: HRS-2329 tablets, HRS-6093 tablets, injectable SHR-9839, HRS-4642 injection, and adbelizumab injection, and agreed to conduct clinical trials. Among them, the total R&D investment for HRS-2329 tablet-related projects is about 116 million yuan, HRS-6093 tablets are about 61.8 million yuan, SHR-9839 related projects are about 128 million yuan, HRS-4642 injections are about 372 million yuan, and adbelizumab injections are about 1.37 billion yuan.
Share
Listen to the news
Hengrui Pharmaceutical announced that the company and its subsidiaries Suzhou Shengdia Biomedical Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd., and Shanghai Hengrui Pharmaceutical Co., Ltd. recently received the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration, involving 5 types of drugs: HRS-2329 tablets, HRS-6093 tablets, injectable SHR-9839, HRS-4642 injection, and adbelizumab injection, and agreed to conduct clinical trials. Among them, the total R&D investment for HRS-2329 tablet-related projects is about 116 million yuan, HRS-6093 tablets are about 61.8 million yuan, SHR-9839 related projects are about 128 million yuan, HRS-4642 injections are about 372 million yuan, and adbelizumab injections are about 1.37 billion yuan.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending